Hydrazone-sulfonate hybrids as potential cholinesterase inhibitors: design, synthesis and molecular modeling simulation

Future Med Chem. 2023 Dec;15(24):2269-2287. doi: 10.4155/fmc-2023-0238. Epub 2023 Nov 23.

Abstract

Aim: Design and synthesis of a series of hydrazone-sulfonate hybrids, 5a-r. Methodology: The inhibitory properties of the synthesized compounds against acetylcholinesterase and butyrylcholinesterase were evaluated using donepezil as the reference standard. Results & conclusion: Compound 5e was identified as the most potent inhibitor of acetylcholinesterase (IC50 = 9.30 μM), and compound 5i was the most potent inhibitor of butyrylcholinesterase (IC50 = 11.82 μM). To confirm the safety of the most potent hits at the used doses, toxicological bioassays were conducted. Molecular docking was performed and the tested derivatives were found to fit well in the active sites of both enzymes. This study provides valuable insights into the potential of hydrazone-sulfonate hybrids as drug candidates.

Keywords: Alzheimer's; cholinesterase; hydrazone–sulfonate; molecular docking; toxicological bioassays.

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease*
  • Butyrylcholinesterase / metabolism
  • Cholinesterase Inhibitors* / chemistry
  • Humans
  • Hydrazones / pharmacology
  • Molecular Docking Simulation
  • Structure-Activity Relationship

Substances

  • Cholinesterase Inhibitors
  • Butyrylcholinesterase
  • Acetylcholinesterase
  • Hydrazones